Centauri Therapeutics is an immunotherapy company focused on infectious diseases. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.
Alphamers® are modular molecules with three components.
A targeting moiety whose structure recognises and binds to a target of interest on the pathogen. This moiety may be a small molecule, a monoclonal antibody or peptide, for example.
A customisable, proprietary linker.
The immunological effector moiety which displays sugar epitopes, leading to the recruitment of pre-existing polyclonal antibody repertoire.
Harnessing the Immune System to Fight Disease
Our immune system has both innate and adaptive arms that combine to protect us from illness following exposure to pathogens.
One key component of the immune system is the natural antibody repertoire, a diverse collection of antibodies, some of which are expressed at high levels in everyone, and comprise IgA, IgM, and IgG sub-populations1, that are constantly circulating in our blood with specificity for individual glycans2. These antibodies are raised and maintained as a result of exposure to foreign antigens in the gut. Natural antibodies have been shown to play an important role in preventing infections to a range of bacterial, viral and parasitic pathogens3,4,5,6.
Centauri Therapeutics’ Alphamer® technology utilises a proprietary antibody recruiting molecule (ARM) to harness the power of the natural antibody repertoire to fight life threatening infectious diseases in the most vulnerable patients.
Kary Mullis PhD
Science consistently produces a new crop of miraculous truths and dazzling devices every year.
Nobel Laureate and inventor of Alphamer concept (1944-2019)